CA2954268C - Process for the preparation of 3-hydroxypicolinic acids - Google Patents

Process for the preparation of 3-hydroxypicolinic acids Download PDF

Info

Publication number
CA2954268C
CA2954268C CA2954268A CA2954268A CA2954268C CA 2954268 C CA2954268 C CA 2954268C CA 2954268 A CA2954268 A CA 2954268A CA 2954268 A CA2954268 A CA 2954268A CA 2954268 C CA2954268 C CA 2954268C
Authority
CA
Canada
Prior art keywords
formula
compound
mixture
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2954268A
Other languages
French (fr)
Other versions
CA2954268A1 (en
Inventor
James M. Renga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corteva Agriscience LLC
Original Assignee
Corteva Agriscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corteva Agriscience LLC filed Critical Corteva Agriscience LLC
Publication of CA2954268A1 publication Critical patent/CA2954268A1/en
Application granted granted Critical
Publication of CA2954268C publication Critical patent/CA2954268C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/803Processes of preparation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present disclosure relates to a process for the preparation of compounds of Formula A: wherein le is a C1-C4 alkyl. 4,6-dibromo-3-hydroxypicolinate esters are prepared from furan-2-yl aminoacetates in one chemical step by use of a bromination-rearrangement reaction.

Description

Cross Reference to Related Applications This application claims the benefit of IJ.S. Provisional Patent Application Serial No.
62/021,868 filed July 8, 2014.
Field The present disclosure concerns a process for the preparation of 4-alkoxy-3-hydroxypicolinic acids. More particularly, the present disclosure concerns a process for the preparation of 4-alkoxy-3-hydroxypicolinic acids from 2-substituted furans.
Background U.S. Patent No. 6,521,622 Bland U.S. Application Serial Numbers 61/747,723 and 14/142,183, describe inter cilia certain heterocyclic aromatic amide compounds of general Formula OY
N

and their use as fungicides.
These disclosures also describe the preparation of 4-alkoxy-3-hydroxypiculinic acids as key intermediates in the preparation of these heterocyclic aromatic amides.
It would therefore be useful to have efficient and scalable process routes to 4-alkoxy-hydroxypicolinic acids from inexpensive raw materials.
Summary The present disclosure concerns a process for the preparation of a compound of Formula A

Date recue / Date received 2021-12-09
2 Br OH
BrN*-CO2R2 A
wherein R2 is a Ci-C4 alkyl.
The compound of Formula A is useful in processes to prepare 4-alkoxy-3-hydroxypicolinic acids of Formula LOH
wherein R1 is a Ci-C3 alkyl.
The compound of Formula A is prepared in a process that comprises the following steps:
a) creating a mixture by adding a brominating agent, a base and water to the compound of Formula B
NH3 + X-wherein X is Cl or Br, and R2 is a C1-C4 alkyl; and b) isolating the compound of Formula A from the mixture.
The compound of Formula B is prepared in a process that comprises the following steps:
a) creating a first mixture by combining together an 0-alkylhydroxylamine hydrohalide salt of the Formula I

0.
R' NH2 HX
wherein X is Cl or Br, and R3 is a Ci-C4 alkyl;
a base, a solvent and the compound of Formula C;

b) isolating a compound of Fonirmla D from the first mixture wherein R3 is a C1-C4 alkyl;
c) mixing the compound of Formula D with an alcohol and an acid compound or acid forming compound and then heating to form a second mixture; and d) isolating a compound of Formula E from the second mixture \ 01 wherein R2 and R3 are independently a C1-C4 alkyl;
c) adding a reducing agent to the compound of Formula E to form a third mixture;
f) isolating a compound of Formula F from the third mixture.

\c' NeACO2R2
3 wherein R2 is a Ci-C4 alkyl;
g) adding a mineral acid to the compound of Formula F to form a fourth mixture; and h) isolating the compound of Formula B from the fourth mixture.
The compound of Formula B may also be prepared in a process that comprises the following steps:
a) creating a first mixture by combining together furan, a Lewis acid and the compound of Formula G

Me0CO2R2 wherein R2 is a CI-CI alkyl and R4 is an acid cleavable group selected from an allyl, a benzyl or a substituted allyl or benzyl group;
b) isolating a compound of Formula H from the first mixture wherein R2 and R4 are as defined in a);
c) adding a mineral acid to the compound of Formula H to form a second mixture; and d) isolating the compound of Formula B from the second mixture. In some embodiments the Lewis acid used in the process is boron trifluoride etherate.
In some embodiments the acid cleavable group is a benzyl group. And in some embodiments the strong acid used in the process is at least one acid selected from the group consisting of hydrochloric acid and hydrobromic acid.
Another aspect of the present disclosure is a novel intermediate produced in the present process, viz., the compound consisting of:
4 NH2 HBr wherein R2 is a Ci-C4 alkyl.
Detailed Description The terms "isolate," "isolating," or "isolation" as used herein mean to partially or completely remove the desired product from the other components of a finished chemical process mixture using standard methods such as, but not limited to, filtration, extraction, distillation, crystallization, centrifugation, trituration, liquid-liquid phase separation or other methods known to those of ordinary skill in the art. The isolated product may have a purity that ranges from <50% to > 50%, and may be purified to a higher purity level using standard purification methods. The isolated product may also be used in a subsequent process step with or without purification.
Cyano(furan-2-yl)methanaminium halide salts of Formula la have been prepared and used as intermediates in the preparation of 3-hydroxypicolinonitriles and 3-hydroxy-picolinoamides of Formula lb as described in Acta Chem. Scand. 19 (1965), pg.
1147-1152, \ 0 CN R3,=-1,x0H

la lb wherein X is Cl, R2 is H or methyl, R3 is H or 2-propyl, and R4 is CN or C(0)NH2.
A. Preparation of Compound of Formula A
In the process described herein, 4,6-dibromo-3-hydroxypicolinate esters of Formula A
are prepared from alkyl 2-amino-2-(furan-2-yl)acetate hydrohalide salts of Formula B in one chemical step by use of a bromination-rearrangement reaction. The starting furan compound of Formula B, as either the HCl or HBr salt and where R2 represents a CI-C4 alkyl, is treated with a suitable brominating agent such as bromine, 1,3-dibromo-5,5-dimethylhydantoin or N-bromosuccinimide. The reaction is preferably conducted using about 4 molar equivalents of bromine. It may be convenient to use an excess of the brominating agent such as a 5%, Br Br2 / base OH
\cla7i)CCO2R2 -11.
H20/alcohol N"CO2R2 A
10% or 15% molar excess, to insure the reaction proceeds to completion. A base is used in the reaction and may be selected from sodium acetate or potassium acetate and the like. The reaction is preferably carried out in a protic solvent or reaction medium such as water, or mixtures of water and an alcohol such as, methanol or ethanol. The temperature at which the reaction is conducted is between about 0 C and about 10 C, preferably between about 0 C
and about 5 C. Upon completion of the addition of the brominating agent, the reaction mixture is allowed to warm to room temperature and stir there for 15-48 hours.
After the reaction is complete, the desired product is recovered by employing standard isolation and purification techniques.
The alkyl 2-amino-2-(furan-2-yl)acetate hydrohalide salt of Formula B may be prepared by the two chemical processes shown in Scheme 1. In Path A, 2-(furan-2-y1)-2-oxoacetic acid (Formula C) is first converted into the 0-alkyl oxime ester of Formula E
(chemical steps a and b), as described in Chemical Research in Toxicology, 24(5) 706-717 (2011) and in PCT Int. Application 2005111001 (2005), and then E is converted into the halide salt of Formula B (chemical steps c and d). Tn Path B, the alkyl 2-methoxy-2-(N-carboxyalkylamino)acetate of Scheme 1 Path A

a, b 0 \ 0/
CO2H Crl&CO2R2 yiNCO2R2 Path B

0 NH CO2 R4 V<'9.
Me0--cCO2R2 ____________ rC 02 R2 Formula G is coupled with furan, as described in Bioorganic and Medicinal Chemistry, 20(11), 3551-3564 (2012), to produce the 2-substituted furan of Formula H
(chemical step e) which is then converted into the halide salt of Formula B (chemical step f).
A. Preparation of Compound of Formula B ¨ Path A
The 0-alkyl oxime ester of Formula E is prepared (chemical steps a and b) by first combining together an 0-alkyl-hydroxylamine hydrobalide salt, 2-(furan-2-y1)-2-oxoacetic acid (Formula C), a base and a solvent, and heating the resulting mixture to produce the oxime acid of Formula D. From one to about three molar equivalents of the 0-alkyl-hydroxylamine hydrohalide salt (R3 is a C1-C4 alkyl) and from about two to about six molar equivalents of the base may be used in this reaction. Suitable bases include trialkylamines, alkali metal carbonates such as sodium carbonate or potassium carbonate, and the like.
Suitable solvents include alcohols such as methanol, ethanol or 2-propanol.
The present reaction is typically conducted with agitation sufficient to maintain an essentially uniform mixture of the reactants and generally requires from about 1 to about 10 hours, preferably 0 NoR3 NoR3 R3ONH2 HX, base R2OH, acid O \
CO2H a CO2H
\

from about 1 to about 5 hours, to proceed to completion. The reaction is usually conducted at between about 25 C and about 85 C, preferably between about 45 C and about 65 C.
After the reaction is complete, the oxime acid of Formula D is recovered by employing standard isolation and purification techniques.
The 0-alkyl oxime acid of Formula D is then converted into the ester of Formula E by esterification in an alcohol solvent in the presence of an acid or an acid-forming compound.
Suitable alcohol solvents include C1-C4 alcohols such as, for example, methanol, ethanol, 1-propanol and 1-butanol. Suitable acids include strong acids such as anhydrous hydrochloric acid, sulfuric acid or p-toluenesulfonic acid, and suitable acid-forming compounds include carboxylic acid halides such as acetyl chloride, acetyl bromide, propionyl chloride or propionyl bromide, and the like. From 0.01 to about 2.0 molar equivalents of the acid or acid forming compound may be used. The reaction is usually conducted at between about 25 C
and about 85 C, preferably between about 45 C and about 65 C for a period of about 8 to about 48 hours, preferably for about 12 to about 24 hours. After the reaction is complete, the oxime ester of Formula E is recovered by employing standard isolation and purification techniques.
The 0-alkyl oxime ester of Formula E is then converted to the aminoester of Formula F by reduction with zinc dust (chemical step c) . This reaction is normally conducted in an alcohol solvent containing 50% aqueous formic acid. Suitable volume ratios of the alcohol solvent to the 50% aqueous formic acid are from about 4:1 to about 1:1, preferably from about 2:1 to about 1:1. Suitable alcohol solvents include C1-C4 alcohols such as, for example, methanol, ethanol, 1-propanol and 1-butanol, preferably, methanol may be used.
From about 2 to about 4 molar equivalents of zinc dust are normally used and the reduction is normally run at 0-10 C for 0.5 to about 2 hours and then at room temperature for about 12 to about 48 hours. After the reaction is complete, the aminoester F is recovered by employing standard isolation and purification techniques.
NoR3 NH2 NH 2 HX
Zn / HCO2H HX
\
CO2R2 \002R2 -"" _____ rCCO2R2 Aminoester F is then converted to the halide salt of Formula B by treatment with a strong acid such as hydrochloric acid, hydrobromic acid or sulfuric acid. From about 2 to about 6 molar equivalents of the strong acid may be used and may be added to a solution of aminoester F in a water immiscible solvent such as diethyl ether, methyl t-butyl ether, 2-methyl furan, dioxane, and the like. The strong acid is normally used in an anhydrous form such as a solution in a non-aqueous solvent such as, for example, acetic acid or dioxane. The strong acid may also be added to the process in the form of a gas or a neat liquid. The strong acid is normally added to aminoester F at from about 0 C to about room temperature, and the resulting mixture then conducted for about 0.5 to about 2.0 hours at room temperature. The halide salt B is recovered by employing standard isolation and purification techniques.
B. Preparation of Compound of Formula B ¨ Path B
Utilizing Path B (Scheme 1), the 2-methoxyaminoacid derivative of Formula G is coupled with furan in the presence of a Lewis acid to provide the 2-substituted furan of Formula H. The compound of Formula G, wherein R2 is a C1-C4 alkyl and R4 is an acid cleavable group selected from allyl, benzyl or a substituted ally' or benzyl group, is placed in a solvent and then treated at room temperature with the Lewis acid, followed immediately by the addition of furan. Suitable solvents for use in this reaction include diethyl ether, methyl t-butyl ether, 2-methyl furan, dioxane, and the like. Suitable Lewis acids include boron trifluoride etherate, aluminum trichloride, tin tetrachloride, and the like.
Relative to compound G, from about 1.0-2.0, preferably from about 1.2- 1.7, molar equivalents of the Lewis acid and from about 2.0-6.0, preferably from about 3.0-5.0, molar equivalents of furan are typically used in this coupling reaction. The reaction is typically conducted for about 10 hours to about 48 hours, preferably for about 18 to about 32 hours at room temperature. After the reaction is complete, the 2-substituted furan of Formula H is recovered by employing standard isolation and purification techniques.
NHco2R4 NHco2R4 ¨
Me0"-kCO2R2 ei j\CO2R2 The compound of Formula H is converted to the compound of Formula B by treatment with a strong acid, such as, hydrochloric acid, hydrobromic acid or sulfuric acid, at room temperature in a polar, carboxylic acid solvent such as acetic acid, propionic acid, and the like. From about 2.0 to about 7.0, preferably from about 4.0 to about 6.0, molar equivalents of the strong acid may be used. The reaction is conducted for about 0.25 to about
5.0 hours, preferably for about 0.5 to about 2 hours at room temperature.
After the reaction is complete, the 2-substituted furan of Formula B is recovered by employing standard isolation and purification techniques.
NHco2R4 NH 2 HX
J = \ 0/ 2 0)NC

The following examples are presented to illustrate the disclosure.
Examples Example la. Methyl 4,6-dibromo-3-hyclroxypicolinate Br NH2 HBr Br2 / Na0Ac OH

SrjNC 02 M e H20 / Me0H
Bres*N'CO2Me To a magnetically stirred solution of methyl 2-amino-2-(furan-2-yl)acetate hydrobromide (0.84 g, 3.56 mmol) and sodium acetate (1.255 g, 15.30 mmol) in 40 nth, of water at 0 (IC was added dropwise a solution of bromine (0.788 ml, 15.30 mmol) in 10 tilt, of Me0H over 30 min, After warming to room temperature for 24 hr, the reaction mixture was filtered through a fitted glass funnel and the white solid was washed with water. Solvent removal gave methyl 4,6-dibromo-3-hydroxypicolinate (577 mg, 1.837 mmol, 51.6%
yield) as a white solid; Mp 180-181 0C (recrystallized from heptane). 1H NMR (600 MHz, Chloroform-d) 611.35 (s, 1H), 7.86 (s, 1H), 4.07 (s, 3H); 13C NMR (151 MHz, Chloroform-d) 6 168.74, 156.02, 136.85, 130.14, 129.92, 124.67, 53.84. HRMS-ESI (m/z) calc'd for [C7H5Br2NO3]f, 308.8636; found, 308.8638.
Example lb. Methyl 4,6-dibromo-3-hydroxypicolinate Br NHCO2CH2Ph 1. HBr, HOAc \ 0/
CO2Me 2. Br2, Na0Ac Br Me0H/H20 To magnetically stirred 33 wt % hydrogen bromide (10.00 ml, 55.2 mmol) in acetic acid was added methyl 2-(((benzyloxy)carbonyl)amino)-2-(furan-2-yl)acetate (2.89 g, 10 mmol). After stirring at room temperature for 1 hr, 150 mL of anhydrous ether was added to give 2.34 g of a grey solid. To a magnetically stirred solution of this grey solid and sodium acetate (3.53 g, 43.0 mmol) in 100 int, of water at 0 C; was added dropwise of a solution of bromine (2.215 ml, 43.0 mmol) in 20 MI of MeOH over 30 min. After stirring at room temperature, the reaction mixture was filtered through a fitted glas funnel.
The off-White solid was dissolved in 75 naL of CH2C1, washed with 5 ml of a saturated aqueous solution of Na2S103 and 5 raL of a saturated aqueous solution of NaCI, and dried (MgSO4). Solvent removal gave methyl 4,6-dibromo-3-hydroxypicolinate (1.43 g, 4.32 mmol, 43.2 %
yield) as an off-white solid; Mp 179-180 0C (recrystallized from heptane). H NMR (400 MHz, Chloroform-d) 6 11.36 (d, J = 0.4 Hz, 1H), 7.86 (m, 1H), 4.07 (s, 3H).

Example 2a. 2-(Furan-2-y1)-2-(methoxyimino)acetic acid 0 NOMe MeONH2 HCI
cOiA

Na2CO3/Me0H
.A magnetically stirred mixture of 2-(furan-2-y1)-2-oxoacetic acid (5.0 g, 35.7 mmol), 0-methylhydroxylamine hydrochloride (5.96 g, 71.4 mmol) and Na2CO3 (15.13 g, mmol) in 100 mt. of Me0H was refluxed for 2 hr. The reaction mixture was cooled to room temperature and concentrated 1-ICI was added slowly until a pH of 2-3 was obtained. Most of the solvent was removed on the rotary evaporator and the residue was diluted with 50 mL of water and 100 mL of ether. Concentrated 1-IC1 was again added to give a pH of 2-3. The aqueous layer was extracted with 2x50 mL of ether. The combined organic layers were washed with 50 mi. of a saturated solution of NaC1, dried (MgSO4) and solvent removed to give 6.58 g of crude 2-(furan-2-y1)-2-(methoxyimino)acetic acid as a viscous oil (crystals formed upon standing).
Example 2b. Methyl 2-(furan-2-y1)-2-(methoxyimino)acetate NOMe NOMe 0_1( Me0H AcCI c0)õ..A
CO2H CO2Me The crude 2-(furan-2-y1)-2-(methoxyimino)acetic acid (Example 2a) was dissolved in 100 int of Me011 and was added to a solution of acetyl chloride (3.82 ml, 53.5 mmol) in 50 triL of A/1KM. After refluxing for 16 hr, solvent was removed on the rotary evaporator and the crude product was added to 100 rilL Et0Ac and 20 mL of water. The organic layer was washed with 20 mil, of a saturated solution of Na.C1, dried (MgSO4.) and solvent removed to give methyl 2-(furan-2-y1)-2-(methoxyimino)acetate (6.35 g, 32.9 mmol, 92 %
yield) as a _ yellow oil. The product is a 4:1 mixture of isomers by H NMR.. Major Isomer: H
NMR (400 MHz, Chloroform-d) 6 7.53 (dd, J = 1.7, 0.6 Hz, 1H), 7.31 (dd, J ¨ 3.5, 0.6 Hz, 111), 6.54 (dd, 3.5, 1.3 Hz, 1H), 4.15 (s, 3H), 3.94 (s, 3H); C NMR (101 MHz, Chloroform-d) 6 162,77, 144,82, 143,80, 142.47, 119.34, 111.78, 63.95, 53.10, HRMS-ESI (m/z) calc'd for [C8H9N04] , 183.0532; found, 183.0539.
Example 2c. Methyl 2-amino-2-(furan-2-ypacetate NOMe NH2 cOjA k Zn CO2Me Me0H / HCO2H CO2Me To a magnetically stirred solution of methyl 2-(furan-2-y1)-2-(methoxyimino)acetate (17.50 g, 96 mmol) in 300 mL of Me0H was added 200 rul_. of a solution of 50%
formic acid in water. The reaction mixture was cooled to 0 0C; (ice bath) and zinc dust (18.74 g, 287 mmol) was added. After stirring at room temperature for 18 hr, the reaction mixture was filtered through a plug of Celite TM and the plug was washed with MeO.H.
Solvent was removed on the rotary evaporator and the yellow residue was dissolved in 50 triL of water, basitied to pH 10 with a saturated solution of Na7C01 and extracted with 3x100 nall, of Et0Ac. After drying (MgSO4) the organic extracts, solvent removal gave 10.2 g of methyl 2-amino-2-(furan-2-yl)acetate as an orange liquid, Example 2d. Methyl 2-amino-2-(furan-2-yl)acetate hydrobromide NH2 NH2 HBr HBr cO_kCO2Me CO2Me Et20 The crude methyl 2-amino-2-(furan-2-yOacetate (Example 2c) was dissolved in nil., of anhydrous ether and with rapid ma.gnetic stirring, 10 ml., of 33 %wt HTBr in acetic acid was added slowly by syringe. After stirring for 30 min, filtration followed by air drying gave methyl 2-amino-2-(furan-2-yl)acetate hydrobromide (12.35 g, 51.8 mmol, 54.2 %
yield) as an off-white solid; Mp 141-142 'C. NMR (400 MHz, DMSO-d6) 8 8.84 (s, 2H), 7.81 (dd, = 1.8, 0.7 Hz, 1H), 6.68 (d, J= 3.3 Hz, 1H), 6.56 (dd, J = 3.3, 1.9 Hz, 1H), 5.59 (s, 1H), 3.77 (s, 31-I); 13C NMR (151 MHz, DMSO-d6) 8 167.44, 145.49, 145.06, 112.14, 111.70, 53.98, 49.73, Example 2e. Methyl 2-(((benzyloxy)carbonyl)amino)-2-(furan-2-yl)acetate NHCO2CH2Ph NHCO2CH2Ph MeOCO2Me NCO2Me BF3.0Et2 "lo a magnetically stirred solution of methyl 2-(((benzyloxy)carbonyl)amino)-2-methoxyacetate (10.89 g, 43 mmol) in 100 mL of anhydrous ether at room temperature under Date recue / Date received 2021-12-09 nitrogen was added boron trifluoride etherate (8.72 ml, 68.8 mmol) followed by the dropwise addition of furan (12.51 ml, 172 mmol) over 2 min. After stirring at room temperature for 24 hr, the reaction mixture was slowly added to 100 mL of a cold, saturated, aqueous solution of NaHCO3. The mixture was extracted with 3x50 mL of Et0Ac, and the combined organic layers were washed with a saturated solution of NaCl, dried (MgSO4) and solvent removed to give 12.7 g of a colorless oil. Column chromatography on silica gel eluting with 20 %
Et0Ac/hexane gave methyl 2-(((benzyloxy)carbonyl)amino)-2-(furan-2-yl)acetate (9.75 g, 33.0 mmol, 77 % yield) as a white solid; Mp 80-81 C. 1H NMR (600 MHz, Chloroform-d)
6 7.35 (m, 6H), 6.35 (m, 2H), 5.77 (d, J = 7.4 Hz, 1H), 5.54 (d, J = 8.2 Hz, 1H), 5.12 (d, J =
2.9 Hz, 2H), 3.77 (s, 3H); 13C NMR (151 MHz, Chloroform-d) 6 169.30, 155.43, 148.62, 142.92, 136.03, 128.54, 128.25, 128.16, 110.69, 108.64, 67.28, 53.08, 51.97.
HRMS-ESI
(m/z) calc'd for [Ci5Hi5N05]', 289.0950; found, 289.0942.
Example 2f. Methyl 2-amino-2-(furan-2-yl)acetate hydrobromide NHCO2CH2Ph NH 2 HBr OJ HBr cOy_c CO2Me HOAc CO2Me To magnetically stirred 33 wt % hydrogen bromide (2.00 ml, 11.04 mmol) in acetic acid was added methyl 2-(((benzyloxy)carbonyl)amino)-2-(furan-2-yl)acetate (579 mg, 2 mmol). After stirring at room temperature for 1 hr, 25 mL of anhydrous ether was added to give methyl 2-amino-2-(furan-2-yeacetate hydrobromide (468 mg, 1.983 mmol, 99 % yield) as a grey solid. 1H NMR (400 MHz, DMSO-d6) 6 8.93 (s, 2H), 7.81 (dd, J = 1.8, 0.8 Hz, 1H), 6.69 (m, 1H), 6.57 (dd, J = 3.3, 1.9 Hz, 1H), 5.61 (s, 1H), 3.78 (s, 3H).

Claims (11)

CLAIMS:
1. A process for the preparation of the compound of Formula A
Br LÇFQH
Br N CO2R2 A
wherein R2 is a C1-C4 alkyl;
which comprises the following steps:
a) creating a mixture by adding a brominating agent and water to the compound of Formula B

c rCCO2R2 wherein X is CI or Br, and R2 is a C1-C4 alkyl; and b) isolating the compound of Formula A from the mixture.
2. The process of Claim 1 wherein the brominating agent is bromine.
3. The process of Claim 1 further including a base.
4. A process for the preparation of the compound of Formula B

yoo2R2 wherein X is CI or Br, and R2 is a C1-C4 alkyl;
which comprises the following steps:

Date recue / Date received 2021-12-09 a) creating a first mixture by combining together an 0-alkylhydroxylamine hydrohalide salt of Formula I, a base, and a compound of Formula C and heating the first mixture wherein X is CI or Br, and R3 is a C1-C4 alkyl;
0.5L/ CO21-I
b) isolating a compound of Foiniula D from the first mixture 4116..

wherein R3 is a C1-C4 alkyl;
c) mixing a compound of Formula D with an alcohol of the formula R2-OH and an acid or acid forming compound and heating to form a second mixture;
d) isolating a compound of Formula E from the second mixture µc. :/y1LCO2R2 E
wherein R2 and R3 are independently a C1-C4 alkyl;
e) adding a reducing agent to the compound of Formula E to form a third mixture;
Date recue / Date received 2021-12-09 0 isolating a compound of Formula F from the third mixture caTLCO2R2 F
wherein R2 is a C1-C4 alkyl;
g) adding a hydrohalide acid to the compound of Formula F to form a fourth mixture; and h) isolating the compound of Formula B from the fourth mixture.
5. The process of Claim 4 wherein the reducing agent is zinc metal.
6. The process of Claim 4 wherein the hydrohalide acid is selected from hydrochloric acid and hydrobromic acid.
7. A process for the preparation of the compound of Formula B

o \C 01)NCO2R2 wherein X is CI or Br, and R2 is a Ci-C4 alkyl;
which comprises the following steps:
a) creating a first mixture by combining together furan, a Lewis acid and a compound of Formula G

Me0-...INCO2R2 wherein R2 is a Cl-C4 alkyl and R4 is an acid cleavable group selected from an allyl, a benzyl or a substituted allyl or benzyl group;

Date recue / Date received 2021-12-09 b) isolating a compound of Foiinula H from the first mixture O
1cLi CO2R2 wherein R2 and R4 are as defined in step a);
c) adding a strong acid to the compound of Formula H to form a second mixture;

and d) isolating the compound of Formula B from the second mixture.
8. The process of Claim 7 wherein the Lewis acid is boron trifluoride etherate.
9. The process of Claim 7 wherein the acid cleavable group is a benzyl group.
10. The process of Claim 7 wherein the strong acid is selected from hydrochloric acid and hydrobromic acid.
11. A compound of the following general formula:
NH2 HBr Oy ( wherein R2 is a C1-C4 alkyl.

Date recue / Date received 2021-12-09
CA2954268A 2014-07-08 2015-07-07 Process for the preparation of 3-hydroxypicolinic acids Active CA2954268C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462021868P 2014-07-08 2014-07-08
US62/021,868 2014-07-08
PCT/US2015/039411 WO2016007532A1 (en) 2014-07-08 2015-07-07 Process for the preparation of 3-hydroxypicolinic acids

Publications (2)

Publication Number Publication Date
CA2954268A1 CA2954268A1 (en) 2016-01-14
CA2954268C true CA2954268C (en) 2022-11-22

Family

ID=55064780

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2954268A Active CA2954268C (en) 2014-07-08 2015-07-07 Process for the preparation of 3-hydroxypicolinic acids

Country Status (15)

Country Link
US (1) US9353060B2 (en)
EP (1) EP3166928B1 (en)
JP (1) JP6560335B2 (en)
KR (1) KR102418462B1 (en)
CN (1) CN106660959B (en)
AR (1) AR101136A1 (en)
BR (1) BR112016030604B8 (en)
CA (1) CA2954268C (en)
CO (1) CO2017000010A2 (en)
ES (1) ES2726927T3 (en)
IL (1) IL249794B (en)
MX (1) MX387903B (en)
TW (1) TWI689495B (en)
WO (1) WO2016007532A1 (en)
ZA (1) ZA201700034B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018014763B8 (en) * 2016-01-22 2023-05-16 Dow Agrosciences Llc PROCESS FOR PREPARING 4-ALKHOXY-3-HYDROXYPICOLINE ACIDS
TW201733985A (en) * 2016-02-29 2017-10-01 陶氏農業科學公司 Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
US10403145B2 (en) * 2017-01-19 2019-09-03 Ford Global Technologies, Llc Collison mitigation and avoidance
JP2020161992A (en) 2019-03-27 2020-10-01 ソニーセミコンダクタソリューションズ株式会社 Imaging system and object recognition system
WO2024018354A1 (en) 2022-07-18 2024-01-25 Pi Industries Ltd. A process for the synthesis of 4-alkoxy-3-hydroxypicolinic acids and intermediates thereof
CN117229167B (en) * 2023-09-08 2025-12-26 湖北梦鑫生物医药科技有限责任公司 A method for preparing a pesticide intermediate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3170401D1 (en) 1980-07-28 1985-06-13 Ciba Geigy Ag Triazoline derivatives and processes for their preparation
EP0061836B1 (en) 1981-03-19 1986-12-30 Imperial Chemical Industries Plc Amide derivatives, processes for preparing them, their use as fungicides and pesticidal compositions containing them
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AU751098B2 (en) 1998-02-06 2002-08-08 Meiji Seika Kaisha Ltd. Novel antifungal compounds and process for producing the same
US6133447A (en) * 1998-02-27 2000-10-17 Novartis Crop Protection, Inc. Process for the preparation of substituted pyridines
AU771975B2 (en) 1998-11-04 2004-04-08 Meiji Seika Kaisha Ltd. Picolinamide derivatives and pest controllers containing the same as the active ingredient
US20030018052A1 (en) 1999-07-20 2003-01-23 Ricks Michael J. Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
EP1516875A1 (en) 1999-07-20 2005-03-23 Dow AgroSciences LLC Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
WO2001005769A2 (en) 1999-07-20 2001-01-25 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
BR0013469B1 (en) * 1999-08-20 2011-01-25 heterocyclic aromatic fungicidal amides, fungicidal composition comprising them, as well as a method for the control or prevention of fungal infestation.
US20050239873A1 (en) 1999-08-20 2005-10-27 Fred Hutchinson Cancer Research Center 2 Methoxy antimycin a derivatives and methods of use
EP1242426B1 (en) * 1999-11-24 2007-10-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
WO2003011857A1 (en) 2001-07-31 2003-02-13 Dow Agrosciences Llc Reductive cleavage of the exocyclic ester of uk-2a or its derivatives and products formed therefrom
US6903219B2 (en) 2001-10-05 2005-06-07 Dow Agrosciences Llc Process to produce derivatives from UK-2A derivatives
AR037328A1 (en) 2001-10-23 2004-11-03 Dow Agrosciences Llc COMPOSITE OF [7-BENCIL-2,6-DIOXO-1,5-DIOXONAN-3-IL] -4-METOXIPIRIDIN-2-CARBOXAMIDE, COMPOSITION THAT UNDERSTANDS AND METHOD THAT USES IT
AU2004243478A1 (en) 2003-05-28 2004-12-09 Basf Aktiengesellschaft Fungicidal mixtures for controlling rice pathogens
DE10347090A1 (en) 2003-10-10 2005-05-04 Bayer Cropscience Ag Synergistic fungicidal drug combinations
WO2005042524A1 (en) 2003-10-30 2005-05-12 Virochem Pharma Inc. Pyridine carboxamide and methods for inhibiting hiv integrase
WO2005111001A1 (en) * 2004-05-19 2005-11-24 Astrazeneca Ab Novel fused heterocycles and uses thereof
JP2009533435A (en) * 2006-04-11 2009-09-17 メルク エンド カムパニー インコーポレーテッド Diaryl substituted alkanes
US8349877B2 (en) 2007-09-26 2013-01-08 Basf Se Ternary fungicidal compositions comprising boscalid and chlorothalonil
JP5670319B2 (en) 2008-05-30 2015-02-18 ダウ アグロサイエンシィズ エルエルシー Method for controlling QoI resistant fungal pathogens
ES2462715T3 (en) * 2008-12-19 2014-05-26 Genentech, Inc. Compounds and methods of use
AU2010289651A1 (en) 2009-09-01 2012-04-05 Dow Agrosciences Llc Synergistic fungicidal compositions containing a 5-fluoropyrimidine derivative for fungal control in cereals
HUE029892T2 (en) 2009-10-07 2017-04-28 Dow Agrosciences Llc Synergistic fungicidal preparations for fungi in cereals
CA2776562A1 (en) 2009-10-07 2011-04-14 Dow Agrosciences Llc Synergistic fungicidal composition containing 5-fluorocytosine for fungal control in cereals
JP2013512935A (en) 2009-12-08 2013-04-18 ビーエーエスエフ ソシエタス・ヨーロピア Pesticide mixture
WO2012070015A1 (en) 2010-11-24 2012-05-31 Stemergie Biotechnology Sa Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases
JP6013032B2 (en) 2011-07-08 2016-10-25 石原産業株式会社 Disinfectant composition and method for controlling plant diseases
BR112014027572A2 (en) 2012-05-07 2017-06-27 Dow Agrosciences Llc macrocyclic picolinamides as fungicides
PL2847188T3 (en) 2012-05-07 2017-07-31 Dow Agrosciences Llc Macrocyclic picolinamides as fungicides
WO2013169664A2 (en) 2012-05-07 2013-11-14 Dow Agrosciences Llc Macrocycle picolinamides as fungicides
KR102148190B1 (en) 2012-12-28 2020-08-26 다우 아그로사이언시즈 엘엘씨 Synergistic fungicidal mixtures for fungal control in cereals
CN105007732B (en) 2012-12-31 2017-07-14 美国陶氏益农公司 It is used as the big ring picolinamide of fungicide

Also Published As

Publication number Publication date
JP2017521416A (en) 2017-08-03
IL249794A0 (en) 2017-03-30
EP3166928A1 (en) 2017-05-17
AR101136A1 (en) 2016-11-23
ES2726927T3 (en) 2019-10-10
ZA201700034B (en) 2018-08-29
MX387903B (en) 2025-03-19
BR112016030604B8 (en) 2022-08-23
IL249794B (en) 2020-07-30
TW201625537A (en) 2016-07-16
BR112016030604B1 (en) 2021-08-24
MX2016017124A (en) 2017-05-10
CN106660959A (en) 2017-05-10
KR102418462B1 (en) 2022-07-08
EP3166928A4 (en) 2018-01-10
KR20170026444A (en) 2017-03-08
CA2954268A1 (en) 2016-01-14
CO2017000010A2 (en) 2017-03-31
TWI689495B (en) 2020-04-01
US20160009647A1 (en) 2016-01-14
CN106660959B (en) 2019-12-03
JP6560335B2 (en) 2019-08-14
BR112016030604A2 (en) 2017-08-22
US9353060B2 (en) 2016-05-31
WO2016007532A1 (en) 2016-01-14
EP3166928B1 (en) 2019-04-03

Similar Documents

Publication Publication Date Title
CA2954268C (en) Process for the preparation of 3-hydroxypicolinic acids
ES2201397T3 (en) PROCEDURE FOR THE PREPARATION OF SILIDENAFILO.
CA3083672A1 (en) Process for the preparation of roxadustat and its intermediates
EP0904268B1 (en) Processes for preparing 3-(1-hydroxyphenyl-1-alkoximinomethyl)dioxazines
EP2980079B1 (en) Method of manufacturing pyridazinone compound
IL186564A (en) Method for producing nicotinic acid derivative or salt thereof
ES2381800T3 (en) Procedure for the production of 5-chloro-2,4-dihydroxypyridine
US20070043107A1 (en) Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane
WO2001047906A1 (en) Process for the production of 5-oxy-7-oxabicyclo-[4.1.0]hept-3-e ne-3-carboxylic acid esters
ES2362616T3 (en) DERIVED FROM IMIDAZOTIAZOL AND PROCESS TO PRODUCE THE SAME.
JP3646225B2 (en) Aromatic ester derivatives, intermediates thereof, and methods for producing them
US20130030183A1 (en) Process for preparing a pharmaceutical compound
KR20010073096A (en) Process for producing oxazole compound
Teus et al. Synthesis and GCP II inhibitory activity of 4 [4-(3-bromobenzyl)-5-hydroxyisoxazol-3-yl] benzoic acid heterocyclic analogs
PL236847B1 (en) 7-dodecanoxy-naringenin-oxime and method for obtaining 7-dodecanoxy-naringenin-oxime
JP2014500850A (en) Process for preparing 5- [1- (4-chlorophenyl) -methylene] -1-hydroxymethyl-2,2-dimethyl-cyclopentanol
EP1632482A1 (en) Intermediates and process for the production of optically active quinolonecarboxylic acid derivatives
JPH0812658A (en) Production of sydnones
KR19990080559A (en) Manufacturing Method of Cemfe derivatives
JPH06100478A (en) Production of 2-iodo-9,9-dialkylfluorene
JP2002187883A (en) 6- (1-Fluoroethyl) -5-iodo-4-pyrimidone and process for producing the same
JPWO1999054297A1 (en) Method for producing chloroalcohol derivatives and intermediates
JPS59112975A (en) Method for producing 4-substituted isoxazoles
JPH02295979A (en) Production of 4-halogenocyclopenta(d)pyrimidine derivative

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200624

EEER Examination request

Effective date: 20200624

EEER Examination request

Effective date: 20200624

EEER Examination request

Effective date: 20200624